JD HEALTH (06618) announced its financial results for the third quarter of 2025, achieving revenue of RMB17.12 billion, a year-on-year increase of 28.7%. Operating profit surged to RMB1.243 billion, up 125.3% compared to the same period last year.

During Q3 2025, JD HEALTH entered strategic partnerships with leading pharmaceutical companies such as Eli Lilly, Innovent Biologics, Eisai China, and Bayer China. Notably, innovative drugs like Eisai's Dayvigo® (lemborexant tablets), Hengrui's Hengqin® (perfluorohexyloctane eye drops) for dry eye syndrome, and Bayer's Daxil® lactulose were exclusively launched on JD HEALTH's platform, reinforcing its position as the premier destination for new and specialty drug debuts.

Beyond pharmaceuticals, health products such as Haleon's next-generation Centrum® Silver vitamins and the first domestic PKU-specific medical food "Te Ai Ben Jia" by Shengtong Medical also debuted on JD HEALTH.

In September 2025, JD HEALTH collaborated with medical device brands like Yuwell, Sinocare, and Medtrum to establish a Smart Interconnected Ecosystem Alliance. Leveraging JD HEALTH's AI-powered platform, the alliance aims to create an integrated smart glucose management system covering monitoring, analysis, intervention, and tracking. Future expansions will include blood pressure, ECG, and respiratory oxygen therapy, targeting a comprehensive service ecosystem from disease prevention to chronic condition management.

Additionally, in September 2025, JD HEALTH partnered with Tongji Medical College Union Hospital to develop a leading smart outpatient service platform. The collaboration will deploy JD HEALTH's AI-powered "JD Doctor Excellence" system for full-process AI-assisted patient services and explore innovative "Internet + Healthcare" models in telemedicine.